首页> 外文期刊>Human vaccines & immunotherapeutics. >Tumor-induced endothelial cell surface heterogeneity directly affects endothelial cell escape from a cell-mediated immune response in vitro
【24h】

Tumor-induced endothelial cell surface heterogeneity directly affects endothelial cell escape from a cell-mediated immune response in vitro

机译:肿瘤诱导的内皮细胞表面异质性直接影响内皮细胞从体外细胞介导的免疫反应中逃逸

获取原文
获取原文并翻译 | 示例
       

摘要

Immune-mediated damage to tumor vessels is a potential means of preventing solid tumor progression. Antiangiogenic cancer vaccines capable of inducing this kind of damage include formulations comprised of endothelial cell-specific antigens. Identification of antigens capable of eliciting efficient vaccination is difficult because the endothelial cell phenotype is affected by surrounding tissues, including angiogenic stimuli received from surrounding tumor cells. Therefore, phenotype endothelial cell variations (heterogeneity) were examined in the context of the development of an efficient vaccine using mass spectrometry-based cell surface profiling. This approach was applied to primary human microvascular endothelial cell (HMEC ) cultures proliferated under growth stimuli provided by either normal tissues (growth supplement from human hypothalamus) or cancer cells (MCF-7, LNCap and HepG2). It was found that tumors induced pronounced, tumor type-dependent changes to HMEC surface targets that in an in vitro model of human antiangiogenic vaccination directly facilitated HMEC escape from cytotoxic T cell-mediated cell death. Furthermore, it was found that tumors influenced the HMEC phenotype unidirectionally and that HMEC imunogenicity was reciprocal to the intensity of tumor-induced changes to the HMEC surface. These findings provide data for the design of tumor-specific endothelial cell based vaccines with sufficient immunogenicity without posing a risk to the elicitation of autoimmunity if administered in vivo.
机译:免疫介导的肿瘤血管损伤是预防实体瘤进展的潜在手段。能够引起这种损伤的抗血管生成癌疫苗包括由内皮细胞特异性抗原组成的制剂。鉴定能够引发有效疫苗接种的抗原是困难的,因为内皮细胞表型受到周围组织的影响,包括从周围肿瘤细胞接受的血管生成刺激。因此,在使用基于质谱的细胞表面谱分析开发有效疫苗的背景下,检查了表型内皮细胞变异(异质性)。该方法适用于在正常组织(人下丘脑的生长补充物)或癌细胞(MCF-7,LNCap和HepG2)提供的生长刺激下增殖的原代人微血管内皮细胞(HMEC)培养物。发现在人抗血管生成疫苗的体外模型中,肿瘤诱导了显着的,肿瘤类型依赖性的HMEC表面靶变化,这直接促进了HMEC从细胞毒性T细胞介导的细胞死亡中逃脱。此外,发现肿瘤单向影响HMEC表型,并且HMEC的免疫原性与肿瘤诱导的HMEC表面变化的强度成反比。这些发现为设计具有足够免疫原性的基于肿瘤特异性内皮细胞的疫苗提供了数据,如果在体内施用,则不会引起引发自身免疫的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号